Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$30.11

-2.61 (-7.98%)

09:48
02/27/18
02/27
09:48
02/27/18
09:48

Aimmune insiders buy $2.16M of shares, Bloomberg reports

Aimmune insiders disclosed yesterday buying a total of $2.16M of the company's shares, Bloomberg reports, citing its compilation of SEC filings. Board member Kathryn Falberg had the largest purchase, worth $960,000, and a total of five insiders bought stock, Bloomberg adds.

  • 02

    Mar

  • 11

    Mar

AIMT Aimmune
$30.11

-2.61 (-7.98%)

02/20/18
DBAB
02/20/18
NO CHANGE
Target $30
DBAB
Buy
Deutsche sees room for multiple players in peanut allergy space
Aimmune Therapeutics' (AIMT) top-line results from the Palisade study suggest that AR101 could be an effective treatment for the desensitization of peanut allergy patients to peanut protein, Deutsche Bank analyst Andrew Peters tells investors in a research note. The analyst, however, believes AR101 "continues to be a potentially challenging therapy from a tolerability and safety perspective" with 20.4% of patients discontinuing therapy for all causes. AR101's profile is "far from suggestive of an all-encompassing option for patients," leaving "meaningful opportunity" for other agents, Peters contends. As such, he sees room for both AR101 and DBV Technologies' (DBVT) Viaskin Peanut. The analyst keeps a Buy rating on DBV shares with a $30 price target.
02/27/18
PIPR
02/27/18
NO CHANGE
Target $62
PIPR
Overweight
Aimmune target raised to $62 following capital raise at Piper Jaffray
Aimmune Therapeutics' recent capital raise extends its runway to mid-2020 and reduces overall clinical and commercial risk for AR101, Piper Jaffray analyst Charles Duncan tells investors in a research note. The analyst continues to see the recent Palisade data as compelling, and even exceeding his expectations, on efficacy and tolerability. To reflect a more favorable commercial outlook, Duncan raised his price target for Aimmune shares to $62 from $60. He reiterates an Overweight rating on the shares.
02/27/18
RBCM
02/27/18
NO CHANGE
RBCM
Outperform
Aimmune price target raised to $62 from $55 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Aimmune to $62, citing the company's PALISADE data announcement that meets and exceeds his expectations for AR101 efficacy and safety. MacKay keeps his Outperform rating, saying the treatment is " well-positioned to disrupt and build the peanut allergy desensitization market" and awaits the full presentation of the phase 3 findings at next week's AAAAI conference.
02/27/18
FBCO
02/27/18
NO CHANGE
Target $45
FBCO
Outperform
Credit Suisse remains surprised by continued pressure at Aimmune
Credit Suisse analyst Vamil Divan notes he was surprised, but not shocked, by the initial pressure seen on Aimmune shares after the release of positive Phase 3 data for its peanut allergy treatment AR101. Some questions regarding the lack of near-term catalysts and on the commercial potential of the product, along with a secondary stock offering, were "rational" reasons for some weakness on the shares, he acknowledges. However, the analyst was shocked by the additional 8% decline seen in the share price on Monday, especially given what he believes is "very positive" data from the PALISADE trial. Divan reiterates an Outperform rating and $45 price target on the shares.

TODAY'S FREE FLY STORIES

SRLP

Sprague Resources

$19.31

-0.24 (-1.23%)

06:05
01/23/19
01/23
06:05
01/23/19
06:05
Hot Stocks
Sprague Resources lowers FY18 adjusted EBITDA view to below $110M-$120M »

Sprague CEO David Glendon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$79.46

-1.78 (-2.19%)

06:05
01/23/19
01/23
06:05
01/23/19
06:05
Earnings
TE Connectivity reports Q1 adj. EPS $1.29, consensus $1.28 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Feb

  • 28

    May

TEVA

Teva

$18.75

-0.06 (-0.32%)

06:04
01/23/19
01/23
06:04
01/23/19
06:04
Upgrade
Teva rating change  »

Teva upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

UNTY

Unity Bancorp

$19.85

0.065 (0.33%)

06:03
01/23/19
01/23
06:03
01/23/19
06:03
Earnings
Breaking Earnings news story on Unity Bancorp »

Unity Bancorp reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPX

Continental Building

$25.55

-0.32 (-1.24%)

06:03
01/23/19
01/23
06:03
01/23/19
06:03
Downgrade
Continental Building rating change  »

Continental Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.40

-0.03 (-2.10%)

06:02
01/23/19
01/23
06:02
01/23/19
06:02
Hot Stocks
Athersys reports 'positive' results from study of MultiStem cell therapy »

Athersys announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$34.45

-0.5 (-1.43%)

05:57
01/23/19
01/23
05:57
01/23/19
05:57
Downgrade
Toll Brothers rating change  »

Toll Brothers downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$17.13

-0.48 (-2.73%)

05:56
01/23/19
01/23
05:56
01/23/19
05:56
Hot Stocks
KBR secures contract for K-SAAT »

KBR announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$10.54

-0.14 (-1.31%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Hot Stocks
Infosys enters partnership with HPE GreenLake »

Infosys announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

WY

Weyerhaeuser

$24.55

-0.54 (-2.15%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SNE

Sony

$48.46

-1.705 (-3.40%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Hot Stocks
Sony announces formation of Sony Home Entertainment & Sound Products »

Sony Visual Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$36.43

-0.74 (-1.99%)

, LEN

Lennar

$43.48

-0.63 (-1.43%)

05:54
01/23/19
01/23
05:54
01/23/19
05:54
Upgrade
D.R. Horton, Lennar rating change  »

D.R. Horton upgraded to…

DHI

D.R. Horton

$36.43

-0.74 (-1.99%)

LEN

Lennar

$43.48

-0.63 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ZNGA

Zynga

$4.33

0.065 (1.53%)

05:53
01/23/19
01/23
05:53
01/23/19
05:53
Periodicals
Zynga founder raising up to $700M for new investment fund, Axios reports »

Zynga founder Mark Pincus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

YELP

Yelp

$35.37

-0.895 (-2.47%)

05:51
01/23/19
01/23
05:51
01/23/19
05:51
Periodicals
SCOTUS won't hear lawsuit over defamatory Yelp reviews, The Verge reports »

The Supreme Court has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

HII

Huntington Ingalls

$196.46

-3.82 (-1.91%)

05:50
01/23/19
01/23
05:50
01/23/19
05:50
Downgrade
Huntington Ingalls rating change  »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

KCDMY

Kimberly-Clark de Mexico

$0.00

(0.00%)

05:49
01/23/19
01/23
05:49
01/23/19
05:49
Downgrade
Kimberly-Clark de Mexico rating change  »

Kimberly-Clark de Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

05:47
01/23/19
01/23
05:47
01/23/19
05:47
Upgrade
Daimler AG rating change  »

Daimler AG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEO

CNOOC

$161.22

-5.52 (-3.31%)

05:44
01/23/19
01/23
05:44
01/23/19
05:44
Hot Stocks
CNOOC announces 2019 business strategy, development plan »

CNOOC announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$35.83

-1.04 (-2.82%)

, AZN

AstraZeneca

$36.27

-0.28 (-0.77%)

05:43
01/23/19
01/23
05:43
01/23/19
05:43
Hot Stocks
Biohaven allowed to proceed with BHV-3241 Phase 3 clinical trial »

Biohaven Pharmaceutical…

BHVN

Biohaven Pharmaceutical

$35.83

-1.04 (-2.82%)

AZN

AstraZeneca

$36.27

-0.28 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

ASML

ASML

$159.39

-3.34 (-2.05%)

05:38
01/23/19
01/23
05:38
01/23/19
05:38
Hot Stocks
ASML, Nikon, Carl Zeiss sign agreement to settle all litigation »

Nikon, ASML Holding, and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

05:36
01/23/19
01/23
05:36
01/23/19
05:36
Hot Stocks
Aslan says varlitinib pre-clinical data published online in Cancers »

Aslan Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAMR

Lamar Advertising

$73.53

-0.59 (-0.80%)

05:35
01/23/19
01/23
05:35
01/23/19
05:35
Recommendations
Lamar Advertising analyst commentary  »

Lamar Advertising price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

ABBV

AbbVie

$88.70

-0.81 (-0.90%)

05:33
01/23/19
01/23
05:33
01/23/19
05:33
Initiation
AbbVie initiated  »

AbbVie assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 28

    Jan

  • 18

    May

PFE

Pfizer

$42.26

-0.26 (-0.61%)

05:31
01/23/19
01/23
05:31
01/23/19
05:31
Downgrade
Pfizer rating change  »

Pfizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

  • 18

    May

XOM

Exxon Mobil

$71.89

-1.09 (-1.49%)

05:30
01/23/19
01/23
05:30
01/23/19
05:30
Hot Stocks
Exxon Mobil, REG enter joint research agreement with Clariant »

ExxonMobil and Renewable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 10

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.